Teva says Phase 3 ecopipam trial halves tic relapse risk in pediatric Tourette syndrome patients

• Teva highlighted a Journal of Child Neurology review of clinical-trial evidence for investigational Tourette drug ecopipam in pediatric patients.
• Results were already presented in completed Phase 2b, Phase 3, and long-term studies, then synthesized in the newly published review.
• Across studies, ecopipam reduced tic severity, sustained benefits over time, and lowered relapse risk versus placebo during continued treatment.
• The review positioned ecopipam’s D1-selective mechanism as a non-antipsychotic approach with fewer typical D2-therapy tolerability drawbacks.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teva Pharmaceutical Industries Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610020800OMX_____CNEWS_EN_GNW1001275861_en) on October 02, 2026, and is solely responsible for the information contained therein.